21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Common pathway signature in lung and liver fibrosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Fibrosis, a progressive accumulation of extracellular matrix components, encompasses a wide spectrum of distinct organs, and accounts for an increasing burden of morbidity and mortality worldwide. Despite the tremendous clinical impact, the mechanisms governing the fibrotic process are not yet understood, and to date, no clinically reliable therapies for fibrosis have been discovered. Here we applied Regeneration Intelligence, a new bioinformatics software suite for qualitative analysis of intracellular signaling pathway activation using transcriptomic data, to assess a network of molecular signaling in lung and liver fibrosis. In both tissues, our analysis detected major conserved signaling pathways strongly associated with fibrosis, suggesting that some of the pathways identified by our algorithm but not yet wet-lab validated as fibrogenesis related, may be attractive targets for future research. While the majority of significantly disrupted pathways were specific to histologically distinct organs, several pathways have been concurrently activated or downregulated among the hepatic and pulmonary fibrosis samples, providing new evidence of evolutionary conserved pathways that may be relevant as possible therapeutic targets. While future confirmatory studies are warranted to validate these observations, our platform proposes a promising new approach for detecting fibrosis-promoting pathways and tailoring the right therapy to prevent fibrogenesis.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: not found
          • Article: not found

          Fibrosis--a common pathway to organ injury and failure.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The impact of TGF-β on lung fibrosis: from targeting to biomarkers.

            Transforming growth factor-β (TGF-β) is extensively involved in the development of fibrosis in different organs. Overproduction or potentiation of its profibrotic effects leads to an aberrant wound healing response during the initiation of fibrotic processes. Idiopathic pulmonary fibrosis (IPF) is a chronic, devastating disease, in which TGF-β\x{2013}induced disturbances of the homeostatic microenvironment are critical to promote cell activation, migration, invasion, or hyperplastic changes. In addition, excess extracellular matrix production contributes in a major way to disease pathogenesis. For this reason, this review will focus on discussing novel data and highlight growing interest in deepening the understanding of the profibrotic role of TGF-β and its direct or indirect targeting for disease modulation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              TGF-beta and fibrosis in different organs - molecular pathway imprints.

              The action of transforming-growth-factor (TGF)-beta following inflammatory responses is characterized by increased production of extracellular matrix (ECM) components, as well as mesenchymal cell proliferation, migration, and accumulation. Thus, TGF-beta is important for the induction of fibrosis often associated with chronic phases of inflammatory diseases. This common feature of TGF-related pathologies is observed in many different organs. Therefore, in addition to the description of the common TGF-beta-pathway, this review focuses on TGF-beta-related pathogenetic effects in different pathologies/organs, i. e., arthritis, diabetic nephropathy, colitis/Crohn's disease, radiation-induced fibrosis, and myocarditis (including their similarities and dissimilarities). However, TGF-beta exhibits both exacerbating and ameliorating features, depending on the phase of disease and the site of action. Due to its central role in severe fibrotic diseases, TGF-beta nevertheless remains an attractive therapeutic target, if targeted locally and during the fibrotic phase of disease.
                Bookmark

                Author and article information

                Journal
                Cell Cycle
                Cell Cycle
                KCCY
                kccy20
                Cell Cycle
                Taylor & Francis
                1538-4101
                1551-4005
                2016
                7 June 2016
                7 June 2016
                : 15
                : 13
                : 1667-1673
                Affiliations
                [a ]Atlas Regeneration, Inc. , Winston-Salem, NC, USA
                [b ]Insilico Medicine, Inc., ETC, Johns Hopkins University , Baltimore, MD, USA
                [c ]Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins University School of Medicine , Baltimore, MD, USA
                [d ]Advanced Academic Programs, Johns Hopkins University , Baltimore, MD, USA
                [f ]The Biogerontology Research Foundation , London, UK
                [g ]Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine , Winston-Salem, NC, USA
                [e ]Pathway Pharmaceuticals, Ltd , Hong Kong, Hong Kong
                Author notes
                CONTACT Eugene Makarev gene@ 123456atlasregeneration.com Atlas Regeneration Inc. , 111 N. Chestnut St., Ste 102, Winston Salem, NC 27101, USA

                Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/kccy.

                Supplemental data for this article can be accessed on the publisher's website.

                Article
                1152435
                10.1080/15384101.2016.1152435
                4957589
                27267766
                4ce333ef-c62c-4602-a239-e9a7d5395f52
                © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

                History
                : 27 January 2016
                : 1 February 2016
                : 4 February 2016
                Page count
                Figures: 1, Tables: 0, References: 54, Pages: 7
                Categories
                Perspective

                Cell biology
                algorithm,bioinformatics,ipf,liver fibrosis,pathway activation,pas,signaling pathway signature

                Comments

                Comment on this article